A survey conducted by Chemical & Engineering News (C&EN) of European and US chemical firms found a wide range of plans for R&D and capital spending for 2015 as a result of economic conditions in the US, Europe and China. The eight companies providing estimates of R&D spending anticipated expenditures totaling $3,574 million, a gain […]
In March, DeCode Genetics published four papers in Nature Genetics on its study sequencing the genomes of 2,636 Icelanders. The research detected rare mutations protecting individuals against disease, and the company reported finding more than 20 million genetic variants. Some of these variants were associated with increased risks for conditions, including a gene associated with […]
The US FDA is experiencing insufficient funding to carry out the steps required by the Food Safety Modernization Act (FSMA) of 2010 (see IBO 12/31/10). According to the Congressional Budget Office, the FDA would have needed $580 million to do this from 2011 to 2015. However, less than half of the amount has been appropriated. […]
Several US attorneys general plan to share their resources to address fraud and QC problems in the $5 billion-a-year herbal-supplements industry. A federal law prevents the FDA from approving supplements by the same process as it does prescription drugs, and harmful supplements are often removed from sale only after they have proven dangerous to consumers. […]
The conclusions of a January meeting of stakeholders in genome engineering were published this month in Science. The group called for research on the safety of using CRISPR-Cas9 technology. According to the stakeholders, understanding the technology’s risks is necessary before endorsing its use in clinical testing, and they recommend several actions in the meantime. The […]
Since October 2014, plummeting crude oil prices have resulted in a 46% drop in the number of US rigs drilling for oil, job cuts, and drops in profits and investment in the US shale industry. Nonetheless, output of shale oil remains steady, with potential for growth over the next two years. Although a decline in […]
This month, the Association for Molecular Pathology (AMP) released the results of its cost analysis and health economic–evaluation models for a number of genomic sequencing–procedure (GSP) CPT codes. The organization also released a template tool for molecular-diagnostic labs to determine the costs of their next-generation sequencing (NGS) assays for GSPs. The AMP performed the analysis […]
This spring, the National Cancer Institute will fund a program called Match to test the effects of a dozen or more new drugs on thousands of patients’ tumors. These so-called basket studies would group tumors from different types of cancers together, and a specific drug would be administered to patients possessing the same mutation. This […]
This month, the FDA approved the first biosimilar drug in the US—Novartis’s Zarxio. An approximate copy of Amgen’s biologic drug Neupogen for increasing the white-blood-cell counts of cancer patients, Zarxio’s approval for all of Neupogen’s uses leads the way for competition and lower prices for biologics in the US. With the FDA now authorized to […]
More than one hundred scientists have cosigned a letter to the journal Nature calling for standardization of antibodies used in research. The authors cited a study conducted in 2008 that found that only around half of six thousand commercial antibodies in common use bound solely to their intended targets. The authors stated that, worldwide, this […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
